{"title":"亚洲人群三阴性乳腺癌的蛋白质组学——需要进一步研究","authors":"K. Vaidyanathan","doi":"10.15406/mojpb.2017.05.00170","DOIUrl":null,"url":null,"abstract":"great need to develop new markers to identify breast cancer at an early stage. There is also a need for newer chemotherapeutic agents, which are more effective and less toxic. Cancers which are negative for ER, PR and HER2 are known as triple negative breast cancers (TNBC). They are very resistant to conventional treatment protocols and hence their management is one of the greatest challenges in contemporary clinical practice. Our own preliminary studies have identified 83 cases that did not express the 3 markers, ER, PR and HER2, i.e. triple negative breast cancer (TNBC) out of a total of 358 cases, 23.2%.2","PeriodicalId":18585,"journal":{"name":"MOJ proteomics & bioinformatics","volume":"55 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proteomics of triple negative breast cancers in Asian population-the need for further studies\",\"authors\":\"K. Vaidyanathan\",\"doi\":\"10.15406/mojpb.2017.05.00170\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"great need to develop new markers to identify breast cancer at an early stage. There is also a need for newer chemotherapeutic agents, which are more effective and less toxic. Cancers which are negative for ER, PR and HER2 are known as triple negative breast cancers (TNBC). They are very resistant to conventional treatment protocols and hence their management is one of the greatest challenges in contemporary clinical practice. Our own preliminary studies have identified 83 cases that did not express the 3 markers, ER, PR and HER2, i.e. triple negative breast cancer (TNBC) out of a total of 358 cases, 23.2%.2\",\"PeriodicalId\":18585,\"journal\":{\"name\":\"MOJ proteomics & bioinformatics\",\"volume\":\"55 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MOJ proteomics & bioinformatics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/mojpb.2017.05.00170\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MOJ proteomics & bioinformatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/mojpb.2017.05.00170","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Proteomics of triple negative breast cancers in Asian population-the need for further studies
great need to develop new markers to identify breast cancer at an early stage. There is also a need for newer chemotherapeutic agents, which are more effective and less toxic. Cancers which are negative for ER, PR and HER2 are known as triple negative breast cancers (TNBC). They are very resistant to conventional treatment protocols and hence their management is one of the greatest challenges in contemporary clinical practice. Our own preliminary studies have identified 83 cases that did not express the 3 markers, ER, PR and HER2, i.e. triple negative breast cancer (TNBC) out of a total of 358 cases, 23.2%.2
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
